| Item Type | Name |
|
Academic Article
|
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.
|
|
Academic Article
|
Clofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
|
|
Academic Article
|
Cord-blood engraftment with ex vivo mesenchymal-cell coculture.
|
|
Concept
|
Graft vs Host Disease
|
|
Academic Article
|
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.
|
|
Academic Article
|
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.
|
|
Academic Article
|
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
|
|
Academic Article
|
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
|
|
Academic Article
|
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
|
|
Academic Article
|
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.
|
|
Academic Article
|
The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
|
|
Academic Article
|
Pleuropericarditis, obliterative bronchiolitis and lymphocytic interstitial pneumonitis after allogeneic haematopoietic stem cell transplantation.
|
|
Academic Article
|
Graft-versus-host disease treatment: predictors of survival.
|
|
Academic Article
|
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.
|
|
Academic Article
|
Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.
|
|
Academic Article
|
Graft-versus-host disease: state of the science.
|
|
Academic Article
|
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
|
|
Academic Article
|
Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
|
|
Academic Article
|
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
|
|
Academic Article
|
Role of ERCP in patients after hematopoietic stem cell transplantation.
|
|
Academic Article
|
Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease.
|
|
Academic Article
|
Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.
|
|
Academic Article
|
Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.
|
|
Academic Article
|
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.
|
|
Academic Article
|
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
|
|
Academic Article
|
Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.
|
|
Academic Article
|
Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.
|
|
Academic Article
|
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.
|
|
Academic Article
|
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
|
|
Academic Article
|
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
|
|
Academic Article
|
Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.
|
|
Academic Article
|
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
|
|
Academic Article
|
Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation
|
|
Academic Article
|
Extracorporeal photopheresis in the treatment of graft-versus-host disease
|
|
Academic Article
|
A prognostic score for acute graft-versus-host disease based on biomarkers
|
|
Academic Article
|
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation
|
|
Academic Article
|
Improved survival after acute graft-versus-host disease diagnosis in the modern era.
|
|
Academic Article
|
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
|
|
Academic Article
|
Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.
|
|
Academic Article
|
Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.
|
|
Academic Article
|
Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.
|
|
Academic Article
|
Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
|
|
Academic Article
|
Long-Term Outcomes after Treatment with Clofarabine???Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
|
|
Academic Article
|
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.
|
|
Academic Article
|
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
|
|
Academic Article
|
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
|
|
Academic Article
|
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
|
|
Academic Article
|
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
|
|
Academic Article
|
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.
|
|
Academic Article
|
Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning.
|
|
Academic Article
|
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.
|
|
Academic Article
|
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.
|
|
Academic Article
|
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.
|
|
Academic Article
|
New and emerging therapies for acute and chronic graft versus host disease.
|
|
Academic Article
|
Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.
|
|
Academic Article
|
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.
|
|
Academic Article
|
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.
|
|
Academic Article
|
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.
|
|
Academic Article
|
Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.
|
|
Academic Article
|
Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.
|
|
Academic Article
|
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.
|
|
Academic Article
|
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.
|
|
Academic Article
|
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
|
|
Academic Article
|
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.
|
|
Academic Article
|
Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America.
|
|
Academic Article
|
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
|
|
Academic Article
|
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
|
|
Academic Article
|
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
|
|
Academic Article
|
A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801.
|
|
Academic Article
|
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
|
|
Academic Article
|
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.
|
|
Academic Article
|
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
|
|
Academic Article
|
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
|
|
Academic Article
|
The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index.
|
|
Academic Article
|
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
|
|
Academic Article
|
Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation.
|
|
Academic Article
|
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
|
|
Academic Article
|
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.
|
|
Academic Article
|
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial.
|
|
Academic Article
|
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.
|
|
Academic Article
|
Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients.
|
|
Academic Article
|
An Exploratory Study on Physical Function in Stem Cell Transplant Patients Undergoing Corticosteroid Treatment for Acute Graft-Versus-Host-Disease.
|
|
Academic Article
|
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD.
|
|
Academic Article
|
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
|
|
Academic Article
|
Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality.
|
|
Academic Article
|
Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia.
|
|
Academic Article
|
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
|
|
Academic Article
|
Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation.
|
|
Academic Article
|
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.
|
|
Academic Article
|
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
|
|
Academic Article
|
Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival.
|
|
Academic Article
|
Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
|
|
Academic Article
|
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
|
|
Academic Article
|
Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
|
|
Academic Article
|
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation.
|
|
Academic Article
|
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
|
|
Academic Article
|
A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study.
|
|
Academic Article
|
Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease.
|
|
Academic Article
|
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
|
|
Academic Article
|
SIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies.
|
|
Academic Article
|
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.
|
|
Academic Article
|
HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection.
|
|
Academic Article
|
A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.
|
|
Academic Article
|
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease.
|
|
Academic Article
|
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type.
|
|
Academic Article
|
Effective treatment of low-risk acute GVHD with?itacitinib monotherapy.
|
|
Academic Article
|
Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.
|
|
Academic Article
|
Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease.
|
|
Academic Article
|
Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.
|
|
Academic Article
|
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.
|
|
Academic Article
|
Patient-reported treatment response in chronic graft-versus-host disease.
|
|
Academic Article
|
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
|
|
Academic Article
|
A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept.
|
|
Academic Article
|
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities.
|
|
Academic Article
|
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
|
|
Academic Article
|
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.
|
|
Academic Article
|
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation.
|
|
Academic Article
|
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.
|